<?xml version="1.0" encoding="UTF-8"?>
<p>Arbidol (Umifenovir) is another influenza-limiting drug that had previously been licensed for use in both China and Russia, for almost several decades [
 <xref rid="B116-vaccines-07-00053" ref-type="bibr">116</xref>,
 <xref rid="B117-vaccines-07-00053" ref-type="bibr">117</xref>]. It was originally developed in Russia and was found to potently inhibit influenza virus fusion with susceptible cell membranes, followed by interferon induction [
 <xref rid="B118-vaccines-07-00053" ref-type="bibr">118</xref>]. Like other broad-spectrum antivirals discussed earlier, besides influenza viruses, Arbidol has been shown to efficiently suppress other viral infections caused by paramyxoviruses and picornaviruses, bunya viruses, rhabdoviruses, reoviruses, togaviruses, hepaciviruses, Ebola virus, arenaviruses, herpesviruses, and the flaviviruses (Zika virus, West Nile virus and Tick-borne encephalitis virus) [
 <xref rid="B119-vaccines-07-00053" ref-type="bibr">119</xref>,
 <xref rid="B120-vaccines-07-00053" ref-type="bibr">120</xref>,
 <xref rid="B121-vaccines-07-00053" ref-type="bibr">121</xref>]. Currently, phase III trial of the Arbidol in ongoing in China and the drug is also due phase IV trial (with an unknown status) in Russia.
</p>
